Cyclo Income Quality from 2010 to 2025

CYTHW Stock  USD 0.03  0.00  0.00%   
Cyclo Therapeutics Income Quality yearly trend continues to be fairly stable with very little volatility. Income Quality is likely to outpace its year average in 2025. Income Quality is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. View All Fundamentals
 
Income Quality  
First Reported
2010-12-31
Previous Quarter
0.73
Current Value
0.76
Quarterly Volatility
0.88242594
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.1 K, Interest Expense of 181.7 K or Total Revenue of 1 M, as well as many indicators such as Price To Sales Ratio of 22.79, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Latest Cyclo Therapeutics' Income Quality Growth Pattern

Below is the plot of the Income Quality of Cyclo Therapeutics over the last few years. It is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. Cyclo Therapeutics' Income Quality historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Quality10 Years Trend
Pretty Stable
   Income Quality   
       Timeline  

Cyclo Income Quality Regression Statistics

Arithmetic Mean0.74
Coefficient Of Variation118.57
Mean Deviation0.42
Median0.80
Standard Deviation0.88
Sample Variance0.78
Range4.6163
R-Value0.24
Mean Square Error0.79
R-Squared0.06
Significance0.37
Slope0.04
Total Sum of Squares11.68

Cyclo Income Quality History

2025 0.76
2024 0.73
2023 0.81
2022 0.98
2021 1.05
2020 0.96
2019 0.87

About Cyclo Therapeutics Financial Statements

Cyclo Therapeutics investors use historical fundamental indicators, such as Cyclo Therapeutics' Income Quality, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cyclo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Quality 0.73  0.76 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.